Literature DB >> 21141490

[Chemical constituents of bear bile].

Qiang Luo1, Quancheng Chen, Yao Wu, Miaomiao Jiang, Zhihong Chen, Xiaokun Zhang, Haifeng Chen.   

Abstract

OBJECTIVE: To study the chemical constituents of bear bile.
METHOD: The compounds were isolated by repeated column HP20 macroporous adsorption resin, Sephadex LH-20, ODS and silica gel as packing materials. The structures were identified on the basis of extensive spectroscopic data analysis and by comparison of their spectral data reported. RESULT: Nine compounds were identified as 4',7-dihydroxyisoflavone (1), 4',7-dihydroxy-6-methoxyisoflavone (2), 4',6,7-trihydroxyisoflavone (3), 4'-methoxy-7-hydroxyisoflavone (4), tauroursodeoxycholic acid (5), taurochenodeoxycholic acid (6), ursodeoxycholic acid (7), chenodeoxycholic acid (8), cholesterol (9).
CONCLUSION: Compounds 1-4 were separated from bear bile for the first time.

Entities:  

Mesh:

Year:  2010        PMID: 21141490

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  4 in total

1.  Preparation and characterization of bear bile-loaded pH sensitive in-situ gel eye drops for ocular drug delivery.

Authors:  Xiaomin Ni; Qin Guo; Yiqing Zou; Yang Xuan; Imran Shair Mohammad; Qing Ding; Haiyan Hu
Journal:  Iran J Basic Med Sci       Date:  2020-07       Impact factor: 2.699

2.  Tauroursodeoxycholic acid binds to the G-protein site on light activated rhodopsin.

Authors:  E Lobysheva; C M Taylor; G R Marshall; O G Kisselev
Journal:  Exp Eye Res       Date:  2018-02-16       Impact factor: 3.467

Review 3.  Substitutes for Bear Bile for the Treatment of Liver Diseases: Research Progress and Future Perspective.

Authors:  Sha Li; Hor Yue Tan; Ning Wang; Ming Hong; Lei Li; Fan Cheung; Yibin Feng
Journal:  Evid Based Complement Alternat Med       Date:  2016-03-21       Impact factor: 2.629

4.  Network pharmacology combined with pharmacodynamics revealed the anti-inflammatory mechanism of Tanreqing capsule against acute-exacerbation chronic obstructive pulmonary disease.

Authors:  Xiao-Xiao Han; Yan-Ge Tian; Xue-Fang Liu; Di Zhao; Xue-Hang Du; Hao-Ran Dong; Su-Xiang Feng; Jian-Sheng Li
Journal:  Sci Rep       Date:  2022-08-17       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.